Sensitivity of empirical metrics of rate of absorption in bioequivalence studies

Pharmaceutical Research

Volumn 17, Issue 5, 2000, Pages 583-588

  Ring, Arne ^a   Tothfalusi, Laszlo ^b   Endrenyi, Laszlo ^c   Weiss, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c NONE

Author keywords

Absorption rate; Bioequivalence; Extended release; Mean absorption time; Relative dispersion

Indexed keywords

CHLORPROTHIXENE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SOLUTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; SUSPENSION; TABLET;

ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CHLORPROTHIXENE; INTESTINAL ABSORPTION; PHARMACEUTICAL SOLUTIONS; PHARMACOKINETICS; SUSPENSIONS; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0034047307     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007521016985     Document Type: Article

References (21)

1. 1. A. Rostami-Hodjegan, P. R. Jackson, and G. T. Tucker. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies - moving the "goalposts" or changing the "game". J. Pharm. Sci. 83:1554-1557 (1994).
2. 2. F. Y. Bois, T. N. Tozer, W. W. Hauck, M.-L. Chen, R. Patnaik, and R. L. Williams. Bioequivalence: performance of several measures of rate of absorption. Pharm. Res. 11:966-974 (1994).
3. 3. L. Endrenyi and P. Al-Shaikh. Sensitive and specific determination of the equivalence of absorption rates. Pharm. Res. 12:1856-1864 (1995).
4. max. Pharm. Res. 12:1634-1641 (1995).
5. 5. T. N. Tozer, F. Y. Bois, W. W. Hauck, M.-L. Chen, and R. L. Williams. Absorption rate vs. exposure: which is more useful for bioequivalence testing? Pharm. Res. 13:453-456 (1996).
6. 6. C. Reppas, L. F. Lacey, O. N. Keene, P. Macheras, and A. Bye. Evaluation of different metrics and indirect measures of rate of drug absorption from extended release dosage forms at steady-state. Pharm. Res. 12:103-107 (1995).
7. 7. L. Endrenyi, F. Csizmadia, L. Tothfalusi, A. H. Balch, and M.-L. Chen. The duration of measuring partial AUCs for the assessment of bioequivalence. Pharm. Res. 15:399-404 (1998).
8. 8. L. Endrenyi, F. Csizmadia, L. Tothfalusi, and M.-L. Chen. Metrics comparing early concentration profiles for the determination of bioequivalence. Pharm. Res. 15:1292-1299 (1998).
9. 9. Food and Drug Administration. "Guidance for Industry: BA and BE Studies for Orally Administered Drug Products-General Considerations". Draft Guidance, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, August, 1999.
10. 10. M. Weiss. A novel extravascular input function for the assessment of drug absorption in bioavailability studies. Pharm. Res. 13:1545-1551 (1996).
11. 11. J. Loetsch, M. Weiss, G. Ahne, G. Kobal, and G. Geisslinger. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Anesthesiology 90:1026-38 (1999).
12. 12. M. Bagli, R. Suverkrup, M. L. Rao, and H. Bode. Mean input times of three oral chlorprothixene formulations. J. Pharm. Sci. 85:434-439 (1996).
13. 13. F. Csizmadia and L. Endrenyi. Model-independent estimation of lag-times with first-order absorption and disposition. J. Pharm. Sci. 87:608-612 (1998).
14. 14. M. Weiss. On the degree of solute mixing in liver models of drug elimination, J. Pharmacokin. Biopharm. 25:363-375 (1997).
15. 15. N. G. Nerella, L. H. Block, and P. K. Noonan. The impact of lag time on the estimation of pharmacokinetic parameters. I. One-compartment open model. Pharm. Res. 10:1031-1036 (1993).
16. 16. M.-L. Chen. An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm. Res. 9:1380-1385 (1992).
17. 17. P. Macheras, M. Symillides, and C. Reppas. An improved intercept method for the assessment of absorption rate in bioequivalence studies. Pharm. Res. 13:1755-1758 (1996).
18. 18. J. Zha, L. Tothfalusi, and L. Endrenyi. Properties of metrics applied for the evaluation of bioequivalence. Drug Info. J. 29:989-996 (1995).
19. 19. V. W. Steinijans and D. Hauschke. Update on the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 28:105-110 (1990).
20. 20. R. P. Basson, A. Ghosh, B. J. Cerimele, K. A. DeSante, and D. C. Howe. Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate. Pharm. Res. 15:276-279 (1998).
21. 21. N. Kaniwa, H. Ogata, N. Aoyagi, T. Takeda, and M. Uchiyama. Power analyses of moment analysis in bioequivalence tests. J. Pharm. Sci. 78:1020-1024 (1989).